AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05055128
Drug: X842
RxNorm normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'X842'. Drug abbreviations can vary and may not be standardized, so without more context about the specific clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive X842 tablets.
Trial: NCT06191523
Drug: Treatment Group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
Trial: NCT04935359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% in water (D5W) solution for infusion
Trial: NCT06088290
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short intravenous push or bolus (according to label)
Trial: NCT05246670
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06205823
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy
Trial: NCT04977674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment with placebo 45 min before the ketamine infusion.
Trial: NCT05715125
Drug: Dose B VTX958
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose B VTX958
Trial: NCT05715125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06751485
Drug: JSKN003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental drug
Trial: NCT06751485
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT06477692
Drug: ENI using IMRT with or without chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
Trial: NCT05051735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04773093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
Trial: NCT05873699
Drug: Hyperpolarized 13-C-pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by Injection
Trial: NCT05933824
Drug: LP-98 injection
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Trial: NCT06112548
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1ml of 30mg/ml ketorolac intraoperative periarticular injection
Trial: NCT06112548
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5ml Adrenaline 1mg/ml intraoperative periarticular injection
Trial: NCT06112548
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Ketorolac {Toradol} introduced every 12 hours after surgery.
Trial: NCT05885854
Drug: XTR003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes.
Trial: NCT05098704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg daily during 24 months
Trial: NCT06681688
Drug: Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the Day of Surgery, eyes in the Control Arm will receive in-office drops administered by study staff according to the following schedule:~* In pre-operative holding: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Immediately prior to surgery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* At the conclusion of surgery while still in the operating room: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)~* Any time in postoperative recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)
Trial: NCT06680258
Drug: TPST-1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα)
Trial: NCT05065528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
Trial: NCT05264727
Drug: Clinisol 15%
RxNorm normalized name: CLINISOL 15% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
Trial: NCT05901311
Drug: LY3537982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05901311
Drug: [¹⁴C]-LY3537982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05901311
Drug: [¹⁴C]-LY3537982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT06538207
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06125054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of placebo (0.9% saline solution i.v. over 40 minutes)
Trial: NCT05139082
Drug: TQB3616 capsules＋ TQB2450 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.
Trial: NCT04798638
Drug: TY-9591 Tablets after a High-fat Meal - Arm1
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Trial: NCT04798638
Drug: TY-9591 Tablets after a High-fat Meal - Arm2
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Trial: NCT05515471
Drug: SHR8058 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR8058 eye drops
Trial: NCT05515471
Drug: saline eye drops.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline eye drops.
Trial: NCT05493332
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W
Trial: NCT05493332
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W
Trial: NCT05559398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
Trial: NCT05332730
Drug: BAT2506 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, subcutaneous administration
Trial: NCT05332730
Drug: Simponi® (EU commercially available product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, subcutaneous administration
Trial: NCT05332730
Drug: Simponi® (US commercially available product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, subcutaneous administration
Trial: NCT06065449
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: standard 8 Gy delivered in a single fraction or 20 Gy delivered in 5 fractions~Arm 2: 16 Gy delivered in a single fraction or 27 Gy delivered in 3 fractions prescribed to planning target volume (PTV).
Trial: NCT05198128
Drug: 0.9 % saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 % saline
Trial: NCT05735197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
Trial: NCT05421923
Drug: SR1375 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of SR1375 orally
Trial: NCT05313828
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tobramycin 4 times /day
Trial: NCT04820842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching tablets.
Trial: NCT05077527
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05371730
Drug: NCR300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of NK cells（NCR300）
Trial: NCT05986877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05452564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
Trial: NCT06422117
Drug: HSK16149 20mg-40mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
Trial: NCT06422117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral, 2 capsules twice daily
Trial: NCT04867057
Drug: Placebo for SAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
Trial: NCT04867057
Drug: Trichomylin for MAD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
Trial: NCT04867057
Drug: Placebo for MAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
Trial: NCT00299351
Drug: Depsipeptide
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05721144
Drug: Nitric Oxide Gas
RxNorm normalized name: Nitric oxide gas
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
Trial: NCT05764122
Drug: BIIB131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05764122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05186285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo.
Trial: NCT03883360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
Trial: NCT04308304
Drug: MK-1942
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.
Trial: NCT04308304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matched to MK-1942 taken BID by mouth.
Trial: NCT05051995
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
Trial: NCT04551482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 IU nasal spray, 4 times per day for 12 weeks
Trial: NCT06680167
Drug: Spinal anesthesia (heavy bupivacaine 0.5%)
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section
Trial: NCT06680167
Drug: spinal anesthesia (hyperbaric Prilocaine 2%)
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section
Trial: NCT05921058
Drug: Secretome
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
Trial: NCT05921058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0,9% infusion
Trial: NCT04768075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion Simulator of Camrelizumab
Trial: NCT06231758
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.
Trial: NCT06556550
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prescribed drug line
Trial: NCT04679870
Drug: GB2064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
Trial: NCT06487416
Drug: Spiriva®Handihaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
Trial: NCT05152641
Drug: BGE-117, 4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGE-117, 4mg Capsules
Trial: NCT05152641
Drug: BGE-117, 12mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGE-117, 12mg Capsules
Trial: NCT05991700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
Trial: NCT06216886
Drug: OnabotulinumtoxinA 100 UNT [Botox]
RxNorm normalized name: onabotulinumtoxinA 100 UNT [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
Trial: NCT05411887
Drug: Rosuvastatin, Olmesartan Medoxomil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olostar Tablet
Trial: NCT06012487
Drug: Low BPV Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)\<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
Trial: NCT05641688
Drug: [18F]PI-2620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
Trial: NCT03847311
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
Trial: NCT06400511
Drug: Placebo Ophthalmic Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be applied twice a day to both eyelid margins.
Trial: NCT06033612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT05352178
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
Trial: NCT05352178
Drug: Androgen receptor targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide
Trial: NCT04748601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qudexy XR Matching capsules
Trial: NCT05934942
Drug: Yasmin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol (EE) and Drospirenone (DRSP)
Trial: NCT06507371
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Trial: NCT06186700
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will take chemotherapy cycle comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous Cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel or dose-dense paclitaxel.
Trial: NCT05622968
Drug: Intravaginal prostaglandin E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insertion of intravaginal Dinoprostone
Trial: NCT06398808
Drug: Arm1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYIL1 capsules 25 mg for oral administration + 50 mg placebo
Trial: NCT06398808
Drug: Arm 2
RxNorm normalized name: Surgitube Arm 2 5/8x50"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
Trial: NCT04735393
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
Trial: NCT04735393
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
Trial: NCT05852431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05749822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet/ day
Trial: NCT05016349
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the approved standard therapy tamoxifen
Trial: NCT04956926
Drug: JS201
RxNorm normalized name: Janus Kinase 2 (JAK2) Inhibitor JS201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS201 is administered intravenously Q3W at the corresponding dose.